

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED**

### **華康生物醫學控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 8622)**

### **CHANGE OF ADDRESS OF HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS IN HONG KONG AND PROPOSED CHANGE OF COMPANY NAME**

#### **(1) CHANGE OF ADDRESS OF HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS IN HONG KONG**

The Board hereby announces that the address of head office and principal place of business of the Company in Hong Kong has been changed to Suite 1004, 10th Floor, Chinachem Golden Plaza, No. 77 Mody Road, No. 16 Science Museum Road, Kowloon, Hong Kong with effect from 15 December 2025.

#### **(2) PROPOSED CHANGE OF COMPANY NAME**

The Board proposes to change the English name of the Company from “Huakang Biomedical Holdings Company Limited” to “Jozyme Group Limited” and, to change the dual foreign name in Chinese of the Company from “華康生物醫學控股有限公司” to “愉悦集團有限公司”.

The Proposed Change of Company Name is subject to (i) the passing of a special resolution by the Shareholders at the EGM to approve the Proposed Change of Company Name; and (ii) the Registrar approving the Proposed Change of Company Name.

A circular containing, among other things, the information in relation to the Proposed Change of Company Name and a notice of the EGM will be despatched to the Shareholders as soon as practicable.

**(1) CHANGE OF ADDRESS OF HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS IN HONG KONG**

The board (the “**Board**”) of directors (the “**Directors**”) of Huakang Biomedical Holdings Company Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) hereby announces that the address of head office and principal place of business of the Company in Hong Kong has been changed to Suite 1004, 10th Floor, Chinachem Golden Plaza, No. 77 Mody Road, No. 16 Science Museum Road, Kowloon, Hong Kong with effect from 15 December 2025.

The Company’s website, email address, telephone number and facsimile number remain unchanged.

**(2) PROPOSED CHANGE OF COMPANY NAME**

The Board proposes to change the English name of the Company from “Huakang Biomedical Holdings Company Limited” to “Joyzyme Group Limited” and to change the dual foreign name in Chinese of the Company from “華康生物醫學控股有限公司” to “愉悅集團有限公司” (the “**Proposed Change of Company Name**”).

The Proposed Change of Company Name is subject to the following conditions:

- (i) the passing of a special resolution by shareholders of the Company (the “**Shareholders**”) at the extraordinary general meeting (the “**EGM**”) to approve the Proposed Change of Company Name; and
- (ii) the Registrar of Companies in the Cayman Islands (the “**Registrar**”) approving the Proposed Change of Company Name.

Subject to the satisfaction of the conditions set out above, the Proposed Change of Company Name will take effect from the date of entry of the new name of the Company on the register maintained by the Registrar. The Company will then carry out all necessary registration and/or filing procedures with the Registrar and the Companies Registry in Hong Kong.

After the Proposed Change of Company Name becoming effective and subject to the confirmation by The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), the Company’s English and Chinese stock short names for trading in the shares of the Company on the Stock Exchange will also be changed.

**Reasons for the Proposed Change of Company Name**

The Board considers that the Proposed Change of Company Name will strengthen the corporate image and identity which will benefit the Group’s growth strategies and better reflect the Group’s current and future business development and direction. The Board believes that the Proposed Change of Company Name is in the best interests of the Company and the Shareholders as a whole.

## **Effects of the Proposed Change of Company Name**

The Proposed Change of Company Name will not affect the rights of any Shareholder or holders of securities of the Company or the Company's daily business operation and its financial position. All existing share certificates of the Company in issue bearing the existing name of the Company will, upon the Proposed Change of Company Name becoming effective, continue to be valid evidence of legal title to the Shares and will continue to be valid for trading, settlement, registration and delivery purposes.

Accordingly, there will not be any arrangement for the free exchange of the existing share certificates for new certificates bearing the new name of the Company. Should the Proposed Change of Company Name become effective, any issue of share certificates thereafter will bear the new name of the Company and the securities of the Company will be traded on the Stock Exchange under the new name.

In addition, subject to the confirmation of the Stock Exchange, the stock short name for trading in the Shares will also be changed after the Proposed Change of Company Name becoming effective. The Company will make further announcement(s) on the Proposed Change of Company Name as soon as practicable after the Proposed Change of Company Name has become effective and will announce the change of the stock short name and change of Company's website following the Proposed Change of Company Name. The stock code of the Company will remain as "8622".

## **GENERAL**

At the EGM to be convened and held, a special resolution will be proposed for the Shareholders to consider and, if thought fit, approve the Proposed Change of Company Name. A circular containing, among other things, information relating to the Proposed Change of Company Name together with a notice of the EGM and the related proxy form, will be despatched to the Shareholders as soon as practicable.

Further announcement(s) will be made by the Company to inform the Shareholders of the results of the EGM, the effective date of the Proposed Change of Company Name and the new stock short names of the Company for trading on GEM of the Stock Exchange and other relevant information as and when appropriate.

On behalf of the Board  
**Huakang Biomedical Holdings Company Limited**  
**Zhang Yujing**  
*Co-Chairman and Executive Director*

Hong Kong, 15 December 2025

*As at the date of this announcement, the Executive Directors are Ms. Zhang Yujing, Dr. Zhou Xunyong, Mr. Zhang Chunguang and Mr. Poon Lai Yin Michael; the Non-executive Directors are Dr. Bu Su and Dr. Xu Ming; and the Independent Non-executive Directors are Dr. Chow Kwok Fai Joseph, Ms. Wang Yachun and Mr. Tsui Wing Tak.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Listed Company Information” page of the Stock Exchange website at [www.hkexnews.hk](http://www.hkexnews.hk) for at least seven days from the date of publication and on the Company’s website at [www.huakangbiomedical.com](http://www.huakangbiomedical.com).*